466 related articles for article (PubMed ID: 36713586)
1. Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma.
Zhang B; Zhang T; Zheng Z; Lin Z; Wang Q; Zheng D; Chen Z; Ma Y
Front Oncol; 2022; 12():1020566. PubMed ID: 36713586
[TBL] [Abstract][Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
[TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma.
Bai X; Lu F; Li S; Zhao Z; Wang N; Zhao Y; Ma G; Zhang F; Su X; Wang D; Ye J; Li P; Ji C
Sci Rep; 2024 Jun; 14(1):12926. PubMed ID: 38839842
[TBL] [Abstract][Full Text] [Related]
6. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
7. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
Li J; Yin J; Li W; Wang H; Ni B
Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a combined cuproptosis and immunogenic cell death prognostic model for diffuse large B-cell lymphoma.
Wang N; Shi S; Li M; Yu X; Ma G
Aging (Albany NY); 2024 Jan; 16(2):1218-1236. PubMed ID: 38284893
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma.
Zhang B; Wang Q; Zhang T; Zheng Z; Lin Z; Zhou S; Zheng D; Chen Z; Zheng S; Zhang Y; Lin X; Dong R; Chen J; Qian H; Hu X; Zhuang Y; Zhang Q; Jin Z; Jiang S; Ma Y
Front Cell Dev Biol; 2023; 11():1159355. PubMed ID: 37152283
[No Abstract] [Full Text] [Related]
11. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
12. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
13. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
14. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
15. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
16. Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer.
Zhang J; Jiang S; Gu D; Zhang W; Shen X; Qu M; Yang C; Wang Y; Gao X
Front Oncol; 2023; 13():1162653. PubMed ID: 37205181
[TBL] [Abstract][Full Text] [Related]
17. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.
Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX
Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376
[TBL] [Abstract][Full Text] [Related]
18. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
Zhang Y; Zhou J; Li H; Liu Y; Li J
BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
[TBL] [Abstract][Full Text] [Related]
19. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
Zhang Q; Zhu Z; Guan J; Zheng C
Front Oncol; 2022; 12():904614. PubMed ID: 35814424
[TBL] [Abstract][Full Text] [Related]
20. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
Front Oncol; 2022; 12():966920. PubMed ID: 36276132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
